Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort

Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort

Introduction Atopic dermatitis (AD) is a highly prevalent, chronic, inflammatory skin disease. Several orally administered Janus kinase inhibitors (JAKis, including baricitinib, upadacitinib and abrocitinib) have received a marketing authorisation for AD.Clinical trials in rheumatoid arthritis (RA)...

Full description

Bibliographic Details
Main Authors: Alain Lescoat, Guillaume Coiffier, Catherine Droitcourt, Emmanuel Oger, Alain Dupuy, Pauline Berthe, Lucie-Marie Scailteux, Delphine Staumont, Pierre Guéret
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/9/e059979.full

Internet

https://bmjopen.bmj.com/content/12/9/e059979.full

Similar Items